Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

A Randomized, Placebo-Controlled Trial Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06640465

Enrollment

150

Registered

2024-10-15

Start date

2024-10-12

Completion date

2025-09-17

Last updated

2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wellness, Health

Keywords

Coenzyme Q10, CoQ10, Geranylgeraniol, GG, Ubiquinol, Ubiquinone

Brief summary

The primary purpose of this study is to compare the safety and effectiveness of commercially available dietary supplements believed to increase coenzyme Q10 (CoQ10) concentrations. An 8-week, randomized, placebo-controlled clinical trial will be conducted comparing the effectiveness of four commercially available dietary supplements on increasing CoQ10 concentrations and self-reported health outcomes.

Interventions

DIETARY_SUPPLEMENTUbiquinol + geranylgeraniol

Combination of ubiquinol and geranylgeraniol

DIETARY_SUPPLEMENTGeranylgeraniol

Geranylgeraniol alone

DIETARY_SUPPLEMENTUbiquinol

Ubiquinol alone

DIETARY_SUPPLEMENTUbiquinone

Ubiquinone alone

OTHERPlacebo

Placebo capsule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Adult males or females age ≥ 40 years 2. Ability to read and speak English

Exclusion criteria

1. Daily use within the past 2 months of any dietary supplements containing CoQ10 or geranylgeraniol (GG) 2. Taking a statin medication within the past 6 months 3. Current daily usage of H2 blockers or PPI medications 4. Current daily use of bisphosphonates 5. Current daily tobacco smoker 6. Known allergies to any substance in the study products 7. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks 8. Current diagnosis of a chronic health condition (e.g., cancer, Crohn's disease) deemed clinically contraindicated for the study protocol. 9. Participant in a clinical trial in the previous 30 days. 10. Participants unable to provide consent

Design outcomes

Primary

Measure	Time frame
Plasma Coenzyme Q10	Baseline and 8 weeks

Secondary

Measure	Time frame	Description
Comprehensive metabolic panel	Baseline and 8 weeks	Alanine aminotransferase (ALT) in units per liter (U/L)
Lipid panel	Baseline and 8 weeks	Low-density lipoprotein (LDL) in milligrams per deciliter (mg/dL)
Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health	Baseline and 8 weeks	Raw scores range from 4 to 20, with higher scores indicating better global physical or mental health compared to the average
Profile of Mood States - Vigor Subscale	Baseline and 8 weeks	Scores range from 0 to 32, with higher scores indicating better energy levels
Short Form 36 (SF-36) - Vitality Subscale	Baseline and 8 weeks	Scores range from 0 to 100, with higher scores indicating greater vitality

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026